Know Cancer

forgot password

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.

Phase 3
18 Years
Not Enrolling
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.

Inclusion Criteria:

- Histologically confirmed, unresectable stage 111B with pericardial or pleural
effusion or stage IV or recurrent non squamous NSCLC.

- Measurable or non-measurable disease per modified RECIST criteria

- ECOG performance status of 0 or 1

- Life expectancy of greater than or equal to 3 months as documented by the

- ability to take oral medications

- competency to give written informed consent

- able to start protocol directed therapy within 7 days from date of randomization

- Hematological function, as follows:

- Absolute neutrophil count (ANC) > = 1.5 x 109/L

- Platelet count > = 100 x 109/L and < = 850 x 109/L

- Hemoglobin > =9 g/dL

- Renal function, as follows:

- Creatinine clearance > 40 mL/min (calculated by Cockcroft Gault formula)

- Urinary protein quantitative value of < = 30 mg in urinalysis or < = 1+ on dipstick
unless quantitative protein is < 500 mg in a 24 hour urine sample

- Hepatic function, as follows:

- Aspartate aminotransferase (AST) < =2.5 x upper limit of normal (ULN) OR AST < 5 x
ULN if liver metastases are present

- Alanine aminotransferase (ALT) < =2.5 x ULN OR ALT < 5 x ULN if liver metastases are

- Alkaline phosphatase < = 2.0 x ULN OR alkaline phosphatase < 5 x ULN if liver or bone
metastases are present

- Total bilirubin < 1.5 x ULN OR total bilirubin < 3 X ULN if subject has UGT1A1
promoter polymorphism (ie, Gilbert syndrome) confirmed by genotyping or Invader
UGT1A1 Molecular Assay prior to randomization Partial thromboplastin (PTT) or
activated partial thromboplastin time (aPTT) < = 1 x ULN and international
normalized ratio (INR) < = 1.5 x ULN

Exclusion Criteria:

- Subjects with adenosquamous histology or an unclear histology subtype (eg, not
otherwise specified) containing greater than 10% squamous cells

- untreated or symptomatic central nervous system metastases. Subjects with a history
of brain metastases are eligible if definitive therapy has been administered (surgery
and/or radiation therapy), there is no planned treatment for brain metastases, and
the subject is clinically stable and is off corticosteroids for at least 2 weeks
prior to randomization.

- Prior chemotherapy as follows: Any prior chemotherapy for advanced non squamous NSCLC

- Any prior adjuvant chemotherapy for non squamous NSCLC within 52 weeks prior to
randomization. Adjuvant chemotherapy completed > 52 weeks prior to randomization is
permitted. Any prior chemoradiation for locally advanced stage III disease.

- Prior (within 30 days of randomization) yellow fever vaccination.

- Central (chest) radiation therapy within 28 days prior to randomization, radiation
therapy within 14 days prior to randomization for peripheral lesions.

- History of pulmonary hemorrhage or gross hemoptysis (approximately 3 mL of bright red
blood or more) within 6 months prior to randomization.

- Prior targeted therapies, including but not limited to:

- AMG 706, inhibitors of VEGF (eg, SU5416, SU6668, ZD6474, SU11248, PTK787, AZD2171,
AEE 788, sorafenib, bevacizumab), or EGFr (eg, panitumumab, cetuximab, gefitinib,

- Known history of allergy or hypersensitivity reaction to paclitaxel or carboplatin.

- Any anticoagulation therapy within 7 days prior to randomization. The use of
low-dose warfarin [ < = 2 mg daily] or low molecular weight heparin or heparin
flushes for prophylaxis against central venous catheter thrombosis is allowed.

- History of arterial or venous thrombosis within 12 months prior to randomization.

- History of bleeding diathesis or bleeding within 14 days prior to randomization.

- Peripheral neuropathy > grade 1 per Common Terminology Criteria for Adverse Events
(CTCAE) Version 3.0.

- Clinically significant cardiac disease within 12 months of randomization, including
myocardial infarction, unstable angina, grade 2 or greater peripheral vascular
disease, cerebrovascular accident, transient ischemic attack, percutaneous
transluminal coronary angioplasty/stent, congestive heart failure, or ongoing
arrhythmias requiring medication.

- History of other primary cancer unless: Curatively resected non melanomatous skin
cancer. Curatively treated cervical carcinoma in situ. Other primary solid tumor
curatively treated with no known active disease present and no curative treatment
administered for the last 3 years

- Any kind of disorder that compromises the ability of the subject to comply with the
study procedures.

- Open wound, ulcer or fracture.

- Uncontrolled hypertension as defined by resting blood pressure > 150/90 mm Hg.
Antihypertensive medications are allowed if the subject is stable on their current
dose at the time of randomization.

- Surgery:

- Major surgical procedures within 28 days prior to randomization

- Minor surgical procedures within 14 days prior to randomization

- Failure to recover from prior surgery

- Placement of a central venous access device (including ports and tunneled or
non-tunneled catheters) within 7 days prior to randomization

- Planned elective surgery while on study treatment

- Core needle biopsy within 7 days prior to randomization

- Not recovered from all previous therapies (ie, radiation, surgery and medications).
Adverse events related to previous therapies must be CTCAE grade < = 1 at screening
or returned to the subject's baseline prior to their most recent previous therapy.

- Participation in therapeutic clinical trials or currently receiving other
investigational treatment(s) within 30 days prior to randomization.

- Pregnant (eg, positive HCG test-serum or urine) or breast feeding woman.

- Any subject not consenting to use adequate contraceptive precautions (eg, hormonal,
barrier or abstinence) during the course of the study and for 6 months after the last

- Known to be human immunodeficiency virus (HIV), hepatitis B surface antigen or
hepatitis C positive.

- Known chronic hepatitis.

- Active infection requiring systemic treatment or any uncontrolled infection < = 14
days prior to randomization.

- History of any medical or psychiatric condition or laboratory abnormality that in the
opinion of the investigator may increase the risks associated with the study
participation or investigational product(s) administration or may interfere with the
interpretation of the results.

- Previously randomized to this study.

- Not available for follow-up assessments or unable to comply with study requirements.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date.

Outcome Time Frame:

Not able to be measured

Safety Issue:


Principal Investigator


Investigator Role:

Study Director

Investigator Affiliation:



South Korea: Korea Food & Drug Administration

Study ID:




Start Date:

July 2007

Completion Date:

February 2013

Related Keywords:

  • Non-Small Cell Lung Cancer
  • lung
  • cancer
  • chemotherapy
  • paclitaxel
  • carboplatin
  • placebo
  • angiogenesis
  • VEGF
  • multi kinase inhibitor
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms